. Author manuscript; available in PMC: 2024 Aug 1.

Published in final edited form as: Curr Treat Options Oncol. 2023 Jun 10;24(8):948–964. doi: 10.1007/s11864-023-01111-1

Table 1.

Recent Therapeutic Updates in Adult T-cell Leukemia/Lymphoma (ATL).

Trial	Design	Population	Response Rates	Survival	Notes
mogamulizumab ⁷⁵	open-label randomized trial of mogamulizumab vs. inv.’s choice	R/R aggressive ATL with ≥ 1 prior systemic therapy	mogamulizumab: ORR: 11% best response: 34% inv.’s choice: ORR: 0% best response: 0%	median PFS: 0.93 (moga) vs. 0.88 m median OS^*: 4.9 (moga) vs. 6.9 m	mogamulizumab is not approved in US for use in R/R ATL but is NCCN listed
CHOP + mogamulizumab ³⁷	single-arm efficacy evaluation of CHOP x 3 followed by mogamulizumab x 8	untreated, transplant-ineligible Japanese patients with ATL	ORR: 87.5%	12-month PFS: 26.6% 12-month OS: 52.6%	mogamulizumab + more intensive chemotherapy is approved in Japan (not US) based on prior studies³⁸
valemetostat ⁹⁷	open-label, single-arm, phase II	R/R aggressive ATL after prior moga or ≥ 1 systemic therapy if moga contraindicated	ORR: 48.0% CR: 20.0%	median PFS: 7.4 m median OS: 16.4 m	valemetostat is approved in Japan for R/R ATL

Crossover allowed.

CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; inv.’s choice, investigator’s choice; moga, mogamulizumab; NCCN, National Comprehensive Cancer Network; ORR, objective response rate; OS, overall survival; PFS, progression-free survival, US, United States.